What is Vyriad?
Headquartered in Rochester, Minnesota, Vyriad operates at the intersection of virology and oncology. The company utilizes advanced platforms derived from vesicular stomatitis virus (VSV), measles, and picornavirus to engineer therapeutics that ignite antitumor immune responses. By programming these viruses to selectively attack cancer cells, Vyriad aims to address significant unmet needs in oncology, focusing on both tumor destruction and the prevention of disease recurrence. The company's market position is bolstered by a robust strategic agreement with Regeneron Pharmaceuticals, which integrates Vyriad's viral platforms with Regeneron's antibody discovery capabilities and PD-1 inhibitor technology, Libtayo.
How much funding has Vyriad raised?
Vyriad has raised a total of $95M across 2 funding rounds:
Series A
$10M
Series B
$85M
Series A (2017): $10M, investors not publicly disclosed
Series B (2025): $85M led by Mayo Clinic, Mr. Harry Stine, Mirae Asset, and Regeneron
Key Investors in Vyriad
Mayo Clinic
A nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research with a focus on complex health conditions.
Regeneron
A leading biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases, including oncology and inflammatory disorders.
Mr. Harry Stine
A prominent private investor and entrepreneur with a history of supporting high-growth technology and life science ventures.
What's next for Vyriad?
With the infusion of $85M, Vyriad is poised to scale its ongoing Phase 1-2 clinical trials, which are currently evaluating the efficacy of its lead VSV-derived platform across multiple cancer indications. The strategic roadmap involves deepening the collaboration with Regeneron to refine combination therapies that enhance the durability of immune responses. As the company transitions further into late-stage clinical development, the focus will likely shift toward regulatory milestones and the potential for broader commercialization of its oncolytic pipeline. This capital provides the necessary runway to sustain long-term research initiatives and solidify Vyriad's role as a leader in the evolving field of viral-based cancer therapeutics.
See full Vyriad company page
